Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days
Open Access
- 1 December 1998
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 9 (12) , 1315-1322
- https://doi.org/10.1023/a:1008441416790
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer.Journal of Clinical Oncology, 1997
- Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: An EORTC early clinical studies group investigationAnnals of Oncology, 1997
- Combination chemotherapy involving orally administered etoposide and JM-216 in murine tumor modelsCancer Chemotherapy and Pharmacology, 1997
- Biotransformation of the platinum drug JM216 following oral administration to cancer patientsCancer Chemotherapy and Pharmacology, 1996
- A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administrationCancer Chemotherapy and Pharmacology, 1995
- Lack of nephrotoxicity of oral ammine/amine platinum (IV) dicarboxylate complexes in rodentsBritish Journal of Cancer, 1993
- NL-FIT: A microcomputer program for non-linear fittingComputer Programs in Biomedicine, 1983
- Reporting results of cancer treatmentCancer, 1981